Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study, which assessed the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), and chemotherapy in the first-line treatment of patients with nonsquamous non—small-cell lung cancer (NSCLC).

This trial was unique, explains Reck, in that it investigated a unique combination comprised of a checkpoint inhibitor, chemotherapy, and an antiangiogenic compound on the basis of the idea that the antiangiogenic compound combined with a checkpoint inhibitor could enhance the efficacy of immunotherapy.

Patients were randomized to receive either the standard of care or the combination therapy. In patients who received the combination, a significant and relevant improvement in progression-free survival and overall survival was been observed in the intent-to-treat population, says Reck. The trial was also notable for its inclusion of patients with pretreated 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

European Lung Cancer Congress

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Dr. Reck on the Rationale of the Impower150 Study